During the corresponding time, Dexcom Inc recorded a revenue increase by 14.99 % year on year, sequentially revenue fell by -5.5 %. While revenue at the Dexcom Inc 's corporate clients
Dexcom Inc's Comment on Sales, Marketing and Customers
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. Its products are used by patients, caregivers, and clinicians globally. The company targets market segments including adults with prediabetes and Type 2 diabetes who do not use insulin, through its Stelo biosensor, the first over-the-counter glucose biosensor approved in the United States. DexCom's recent products include the Dexcom G7 Continuous Glucose Monitoring System and the Dexcom G7 15 Day Continuous Glucose Monitoring System.
Dexcom G7 Continuous Glucose Monitoring System Launch and New Initiatives for College Athletes with DiabetesIn a significant stride toward enhancing diabetes management, DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, has announced the upcoming launch of the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System in the United States. Set to debut on December 1, 2023, this new device is designed for people over the age of 18 living with diabetes, promising to revolutionize how individuals monitor and manage their glucose levels. The Dexcom G7: A New Era in Glucose Monitoring The Dexcom G7 15 Day CGM system features a sleek, comfortable design that continuously monitors glucose leve...
In a significant legal development, the Portnoy Law Firm has announced a class-action lawsuit against DexCom, Inc., a prominent player in the continuous glucose monitoring industry. The announcement, made on November 6, 2025, states that the lawsuit is on behalf of investors who purchased DexCom securities between July 26, 2024, and September 17, 2025. The lawsuit contends that DexCom investors were adversely affected during this period due to alleged misrepresentations that impacted stock prices.According to filings, the legal action targets potential inaccuracies and misleading information disseminated by DexCom during the defined class period. Although specific grievances were not detailed in the initial ...
Investor Alert: DexCom, Inc. Faces Class Action Lawsuits Amid Allegations of Misleading Statements and Unauthorized Device ModificationsDexCom, Inc. (NASDAQ: DXCM), a leader in continuous glucose monitoring systems, is under legal scrutiny as multiple class action lawsuits have been filed against the company. These lawsuits claim that DexCom and certain top executives violated the Securities Exchange Act of 1934 by making materially false and misleading statements and failing to disclose substantial adverse information. The central allegations revolve around unauthorized design changes to their flagship glucose monitoring devices, the G6 and G7, rendering them less reliable and a potential health risk to us...
Dexcom Unveils Revolutionary Glucose Biosensing Innovations and Clinical Achievements at EASD 2025DexCom, Inc. (Nasdaq: DXCM), the leading innovator in glucose biosensing technology, is set to make significant strides at the upcoming 61st annual European Association for the Study of Diabetes (EASD) Conference in Vienna. This prestigious event provides a global platform for Dexcom to not only showcase their advancements in diabetes management but also to unveil new evidence demonstrating the profound benefits and cost-effectiveness of their cutting-edge glucose biosensing solutions.In the realm of chronic disease management, few tools have proven as transformative as continuous glucose monitoring (CGM). Dexc...
Understanding the DexCom Situation: Investor s Rights and Legal ActionsThe legal landscape surrounding DexCom, Inc. (NASDAQ: DXCM) has taken a significant turn, as Rosen Law Firm, a global authority in investor rights, has initiated calls for DexCom investors to secure counsel before the fast-approaching deadline for a securities class action. This movement spotlights crucial issues regarding investor transparency, corporate accountability, and the performance of healthcare technology companies in volatile market conditions. Background on Legal ActionsRosen Law Firm has specifically advised purchasers of DexCom securities, who bought shares between January 8, 2024, and July 25, 2024, to pay close attention ...
The Transformative Role of Continuous Glucose Monitoring in Diabetes Management In the rapidly evolving landscape of diabetes management, DexCom, Inc. emerges as a pivotal player, showcasing its real-time continuous glucose monitoring (CGM) technology at the renowned European Association for the Study of Diabetes (EASD) Conference. Scheduled for September 9, 2024, in Edinburgh, Scotland, this symposium underlines the company s commitment to advancing diabetes care through innovative technology a commitment that could significantly impact both patient outcomes and Dexcom’s market positioning. Key Performers and Expert Insight The EASD Conference is renowned for gathering leading experts in the field of diab...
Class Action Storm Hits DexCom, Stellantis, Symbotic, and NANO Nuclear Energy: What Shareholders Need to KnowAs the financial landscape evolves, so do the complexities and challenges faced by shareholders and investors. Recently, Johnson Fistel, LLP, a law firm renowned for its focus on shareholder rights, announced the launch of class action lawsuits targeting DexCom, Inc. (NASDAQ: DXCM), Stellantis N.V. (NYSE: STLA), Symbotic Inc. (NASDAQ: SYM), and NANO Nuclear Energy Inc. (NASDAQ: NNE). The firm urges affected investors to review crucial deadlines and come forward if they wish to participate in these lawsuits. Timeline for ActionFor investors who have suffered financial setbacks due to the aforementione...
Dexcom Expands AID Partnership Into The Netherlands: Introducing the Omnipod 5 and Dexcom G6 for Easier Diabetes ManagementEDINBURGH, Scotland - DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, is thrilled to announce the expansion of its partnership into the Netherlands. This development brings hope and enhanced diabetes management to people living with Type 1 diabetes in the country.Type 1 diabetes is a chronic disease that affects the body s ability to produce insulin, a hormone necessary to regulate blood sugar levels. Currently, more than 100,000 individuals in the Netherlands are impacted by this condition, with an additional estimated 10...
Dexcom Expands Technological Innovations and Coverage for Diabetes Management: A Strategic Move Towards a Healthier Future Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for individuals managing diabetes, has unveiled a series of game-changing advancements and initiatives in 2023. With significant strides in both technology and accessibility, the company is poised to strengthen its market leadership and further improve the lives of diabetes patients worldwide. Direct Connection to Apple Watch: Dexcom G7 s Technological Leap In a major leap for digital health integration, Dexcom announced that its latest CGM system, the Dexcom G7, now connects directly to the A...
Dexcom Demonstrates Leadership in AID and CGM s Impact on Type 2 Diabetes Management: New Data Presented at ATTDEDINBURGH, Scotland - DexCom, Inc. (NASDAQ: DXCM), the leading provider of real-time continuous glucose monitoring (CGM) for individuals with diabetes, recently revealed compelling new clinical evidence that reinforces the value of using Dexcom CGM in automated insulin delivery (AID) systems. Alongside this, Dexcom showcased data illustrating the significant benefits of CGM usage for individuals managing Type 2 diabetes, as well as groundbreaking evidence establishing a direct association between CGM and improved health outcomes.The evidence presented by Dexcom at the ATTD conference (Advanced Tech...
Dexcom Inc’s Comment on Sales, Marketing and Customers
DexCom, Inc. is a medical device company that designs, develops, and commercializes continuous glucose monitoring (CGM) systems for diabetes and metabolic health management. Its products are used by patients, caregivers, and clinicians globally. The company targets market segments including adults with prediabetes and Type 2 diabetes who do not use insulin, through its Stelo biosensor, the first over-the-counter glucose biosensor approved in the United States. DexCom's recent products include the Dexcom G7 Continuous Glucose Monitoring System and the Dexcom G7 15 Day Continuous Glucose Monitoring System.
Sources:
Dexcom Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Dexcom Inc’s corporate clients.
For your research, we’ve provided 9 tables on Dexcom Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
69.86 %